CLS receives approximately SEK 12.2 million through the exercise of subscription warrants of series TO3
Clinical Laserthermia Systems AB (publ) (“CLS” or the “Company”) carried out a rights issue of units (the “Rights Issue”) and a directed issue of units (the “Directed Issue”) in April 2021. The units issued in the Rights Issue and the Directed Share Issue consisted of shares and subscription warrants from the TO3 (the “Subscription Warrants”) and TO4 series. The exercise period for the TO3 subscription warrants ran during the period from April 11, 2022 until April 25, 2022. In total, 3,484,241 Subscription Warrants were exercised for subscription of new class B shares, corresponding to an